Alvotech Announces Strategic Refinancing Agreement
June 07, 2024 04:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a...
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
June 05, 2024 15:12 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
“Collaboration in clinical trials ensures data integrity and safety, advancing both organizations' missions and improving patient care,” says Dr. Jennifer
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024 08:05 ET
|
Alvotech
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies í New York dagana 5.-6. júní 2024
May 29, 2024 08:04 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur í heilbrigðisráðstefnu Jefferies fjárfestingabankans, í New York dagana 5.-6. júni nk. Alvotech mun halda kynningu og funda með fjárfestum og viðskiptavinum á...
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024 08:04 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:15 ET
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period...
Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
May 21, 2024 17:14 ET
|
Alvotech
Heildartekjur á fyrsta ársfjórðungi 2024 jukust í 37 milljónir dollara, úr 16 milljónum dollara á sama tímabili í fyrraFramlegð á fyrsta fjórðungi 2024 var 17 milljónir dala, sem er 40 milljóna...
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024 17:14 ET
|
Alvotech
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last yearGross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last...
Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
May 21, 2024 08:01 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories SA, dótturfyrirtæki Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) um sölu- og...
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024 08:01 ET
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and...